Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Hypericin. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Hypericin. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Hypericin. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Hypericin. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Hypericin. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Hypericin. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Hypericin. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Hypericin. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Hypericin. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hypericin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Hypericin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Hypericin. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Hypericin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Hypericin. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Hypericin. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Hypericin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Hypericin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Hypericin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Hypericin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Hypericin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Hypericin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hypericin. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Hypericin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Hypericin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hypericin. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Hypericin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Hypericin. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Hypericin. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Hypericin. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Hypericin. |
| Cladribine | Hypericin may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Hypericin. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Hypericin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Hypericin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Hypericin. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Hypericin. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Hypericin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Hypericin. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Hypericin. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Hypericin. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Hypericin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Hypericin. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Hypericin. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Hypericin. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Hypericin. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Hypericin. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Hypericin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Hypericin. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Hypericin. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Hypericin. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Hypericin. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Hypericin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Hypericin. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Hypericin. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Hypericin. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Hypericin. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Hypericin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hypericin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Hypericin. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Hypericin. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hypericin. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Hypericin. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Hypericin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Hypericin. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Hypericin. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Hypericin. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Hypericin. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Hypericin. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Hypericin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Hypericin. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hypericin. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Hypericin. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Hypericin. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Hypericin. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Hypericin. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hypericin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Hypericin. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Hypericin. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Hypericin. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hypericin. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hypericin. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Hypericin. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Hypericin. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Hypericin. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Hypericin. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Hypericin. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Hypericin. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Hypericin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hypericin. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hypericin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Hypericin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Hypericin. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Hypericin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Hypericin. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Hypericin. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hypericin. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Hypericin. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Hypericin. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Hypericin. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Hypericin. |